ValiRx Secures £1.16M Funding to Advance Cancer Therapeutics and Women's Health Pipeline
Key Insights
ValiRx (search), an AIM-listed life sciences company, raised £1.155 million through equity financing at a 17% discount to fund early-stage cancer therapeutics and women's health programs.
The funding will support in-licensing activities, intellectual property expansion, preclinical development, and growth of the company's animal health division.
Key near-term milestones include patent grants for the Cytolytix (search) programme and validation of ValiRx (search) Animal Health's primary indication, with readouts expected between July and November.
ValiRx (search), the AIM-listed life sciences company focused on early-stage cancer therapeutics and women's health, has successfully raised up to £1.155 million through a comprehensive financing package comprising a placing, subscription, and planned retail offer at 0.2p per share. The funding comes at a critical juncture as the company advances its pipeline of therapeutic assets and expands its intellectual property portfolio.
Financing Structure and Market Response
The equity raise consisted of a placing of 500 million new shares that generated the majority of proceeds, supplemented by a £5,000 director subscription and up to £150,000 from a retail offer targeting smaller investors. Shard Capital Partners (search) served as the sole broker for the transaction.
The market responded negatively to the financing terms, with shares falling 17% to 0.2p, matching the issue price that represented a 17% discount to the previous closing price. Subscribers will receive one warrant for every new share acquired, exercisable at 0.28p—a 40% premium to the issue price—subject to shareholder approval at the company's annual general meeting in June.
The enlarged share capital will rise to 1.32 billion shares, assuming full take-up of the retail offer.
Strategic Use of Proceeds
ValiRx (search) outlined a focused deployment strategy for the raised capital, targeting four key areas: in-licensing activity, intellectual property expansion, preclinical development, and growth of its animal health division. This approach aligns with the company's capital-efficient model that emphasizes licensing, partnerships, and non-dilutive funding rather than traditional high-cost biotech development.
Pipeline Milestones and Development Timeline
The company has identified several near-term catalysts across its portfolio. Key milestones include the anticipated grant of patents for its Cytolytix (search) programme, validation of the primary indication for ValiRx (search) Animal Health, and progression of non-dilutive funding applications with readouts expected between July and November.
ValiRx (search) is actively progressing the in-licensing of an asset from McGill University, with potential for a cross-license to its animal health subsidiary. The company also plans to complete a drug repurposing screen that could support future grant funding or facilitate a partnering deal.
Management Perspective
Chief executive Mark Eccleston emphasized that the fundraising was strategically designed to unlock several near-term catalysts across the portfolio. He highlighted the company's capital-efficient model built around licensing, partnerships, and non-dilutive funding as an alternative to traditional high-cost biotech development approaches.
Chairman Martin Gouldstone expressed confidence in the company's trajectory, stating that ValiRx (search) was building an asset-rich business that he believed was "massively undervalued" in the current market environment.
Therapeutic Focus Areas
ValiRx (search) maintains its strategic focus on early-stage cancer therapeutics and women's health, representing significant areas of unmet medical need. The company's diversified approach includes both human therapeutics and animal health applications, potentially providing multiple pathways for value creation and risk mitigation across its development portfolio.